BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 13, 2008
View Archived Issues
Pfizer compounds reveal potential of c-Met inhibition for cancer treatment
Read More
Deciphera describes activity and optimization of bcr-Abl kinase inhibitor DCC-2036
Read More
Novel therapeutic agents for cancer covered in recent patent literature
Read More
Bristol-Myers Squibb develops a novel and potent statin with reduced myotoxicity
Read More
Org-52186 shows potential for treating anxiety and depression
Read More
Preclinical data on Pfizer's alpha2delta ligand PD-0200390 reported
Read More
Cleveland BioLabs completes enrollment in phase II clinical trial of Curaxin in prostrate cancer
Read More
Dutch health authorities license Vaccinogen to manufacture OncoVAX anticolon cancer vaccine
Read More
Cytopia and Cancer Therapeutics enter anticancer drug development collaboration
Read More
Dainippon Sumitomo initiates phase I clinical development of immune response modifier
Read More
iCo Therapeutics acquires worldwide rights to iCo-009 for systemic fungal infections
Read More
Microbix forms Klarogen Biotherapeutics and acquires ImaRx's clot busting drug urokinase
Read More
Mistral Pharma not to pursue combination with U.S. specialty pharmaceutical company
Read More
OrthoLogic reports positive safety data from phase I clinical trial of AZX-100
Read More
Endogenous inhibitor of corneal lymphangiogenesis shows potential in corneal transplantation model
Read More
Dana-Farber Cancer Institute initiates phase I trial of EntreMed's ENMD-2076
Read More
New class of topical antioxidants for the treatment of retinal disorders reported by Sirion
Read More
FDA grants approval to Osiris for expanded access treatment program for Prochymal in GVHD
Read More
BiPar expands phase II clinical trial programs for BSI-201 to include ovarian cancer
Read More
FDA approves Strattera for maintenance of ADHD in children and adolescents
Read More
Recent patents disclose new agents for endocrine disorders
Read More
FDA grants orphan drug designation for palifosfamide in soft tissue sarcoma
Read More
Medarex initiates phase II trials in ulcerative colitis and rheumatoid arthritis
Read More
Active Biotech moves Anyara into phase III in renal cancer
Read More